Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A compound represented by structure I



wherein

R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group;

R^1 is independently -H, -OH or –O-Pg; R^2 is -H, $-CH_3$, $-NH_2$, or -NH-Pg;

R^3 is -H, $-CH_3$, $-CH_2CONH_2$, $-CH_2CONH$-Pg, $-CH_2CH_2NH_2$, or-CH_2CH_2NH-Pg;

R^5 is -OH, -OSO_3H, or –OPO_2HR^a, where R^a is hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, phenyl, phenoxy, *p*-halophenyl, *p*-halophenoxy, *p*-nitrophenyl, *p*-nitrophenoxy, benzyl, benzyloxy, *p*-halobenzyl, *p*-halobenzyloxy, *p*-nitrobenzyl, or *p*-nitrobenzyloxy; R^6 is -H, -OH, or –OSO_3H; R^7 is -H or –CH_3; R^4 and R^8 are independently, hydrogen, or hydroxy and at least one of R^4 and R^8 is a sugar moiety of the formula



or



where R^9 is independently -H, -OH, -N_3, -O-Pg, -NH_2, -NH-Pg, –OPO_2R^a, or a second sugar moiety consisting of one to three sugar units selected from the group consisting of



,



,



,



,

and mixtures thereof, wherein R^{9a} is -H, -OH, -N_3, -NH_2, -O-Pg, or -NH-Pg, R^{9b} is –OPO_2R^a, -OSO_3H, -H, -NH_2, -OH, -O-Pg, or -NH-Pg, R^{9c} is –CH_3, -CH_2OH, -CH_2N_3, -CH_2OSO_3H, -CH_2NH-Pg, -CH_2O-Pg, -CO_2H, or –CO_2-Pg, where R^a is as defined above, and no more than one R^9 is

represented by said second sugar moiety; and each Pg is independently a protecting group; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

Claim 2 (original): The compound of Claim 1 wherein R is



, or

where A, B, C and D are independently hydrogen, C_1-C_{12} alkyl, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, C_1-C_{12} alkylthio, halo, or-O-$(CH_2)_m$-$[O$-$(CH_2)_n]_p$-O-(C_1-C_{12} alkyl) or -O-$(CH_2)_q$-X-E; m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4; X is pyrrolidino, piperidino or piperazino; and E is hydrogen, C_1-C_{12} alkyl, C_3-C_{12} cycloalkyl, benzyl or C_3-C_{12} cycloalkylmethyl.

Claim 3 (original): The compound of claim 2 wherein R^1 is hydroxy at each occurrence; R^2, R^3, and R^7 are each methyl; R is a moiety of the formula



or ;

R^4 is hydroxy; R^3 is $-OPO_2HR^a$, where R^a is C_1-C_4 alkyl or C_1-C_4 alkoxy; R^8 is a sugar moiety of the formula



; or

a pharmaceutically acceptable salt or solvate thereof.

Claim 4 (original): The compound of claim 3 wherein R^5 is hydroxy; R is a moiety of the formula

where D is hydrogen or C_3-C_7 alkoxy; R^8 is a moiety of the formula



where R^9 is independently hydrogen, hydroxy, amino, or a moiety of the formula



where R^{9b} is $-OPO_2R^a$, $-OSO_3H$, -H, $-NH_2$, -OH, -O-Pg, or -NH-Pg and n is 1, 2, or 3; or a pharmaceutically acceptable salt or solvate thereof.

Claim 5 (currently amended): The compound of claim 4 wherein D is n-pentoxy~~;~~ and R^9 is ~~and R^{9a} are~~ independently hydroxy or amino; and R^{9b} is -OH or $-OPO_2R^a$; or a pharmaceutical salt or solvate thereof.

Claim 6 (currently amended): The compound of claim 5 wherein R^9 is hydroxy at each occurrence; ~~and R^{9b} is $-OPO_2R^a$, where R^a is methyl or methoxy;~~ or a pharmaceutical salt or solvate thereof.

Claim 7 (original): A pharmaceutical formulation comprising one or more pharmaceutical carriers, diluents, or excipients and a compound of claim 1.

Claim 8 (previously presented): A method of inhibiting fungal activity comprising administering to a recipient in need of such inhibition an effective amount of a compound represented by structure I:



wherein R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group; R^1 is independently -H, -OH or –O-Pg; R^2 is -H, $-CH_3$, $-NH_2$, or -NH-Pg; R^3 is -H, $-CH_3$ – CH_2CONH_2, $-CH_2CONH$-Pg, $-CH_2CH_2NH_2$, or-CH_2CH_2NH-Pg; R^5 is -OH, $-OSO_3H$, or – OPO_2HR^a, where R^a is hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, phenyl, phenoxy, *p*-halophenyl, *p*-halophenoxy, *p*-nitrophenyl, *p*-nitrophenoxy, benzyl, benzyloxy, *p*-halobenzyl, *p*-halobenzyloxy, *p*-nitrobenzyl, or *p*-nitrobenzyloxy; R^6 is -H, -OH, or $–OSO_3H$; R^7 is -H or $–CH_3$; R^4 and R^8 are independently, hydrogen, or hydroxy and at least one of R^4 and R^8 is a sugar moiety of the formula



where R^9 is independently -H, -OH, $-N_3$, -O-Pg, $-NH_2$, -NH-Pg, $-OPO_2R^a$, or a second sugar moiety consisting of one to three sugar units selected from the group consisting of



and mixtures thereof, wherein R^{9a} is -H, -OH, $-N_3$, $-NH_2$, -O-Pg, or -NH-Pg, R^{9b} is $-OPO_2R^a$, $-OSO_3H$, -H, $-NH_2$, -OH, -O-Pg, or -NH-Pg, R^{9c} is $-CH_3$, $-CH_2OH$, $-CH_2N_3$, $-CH_2OSO_3H$, $-CH_2NH$-Pg, $-CH_2O$-Pg, $-CO_2H$, or $-CO_2$-Pg, where R^a is as defined above, and no more than one R^9 is represented by said second sugar moiety; and each Pg is independently a protecting group; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

Claim 9 (original): The method of Claim 8 wherein R is



, or

where A, B, C and D are independently hydrogen, C_1-C_{12} alkyl, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, C_1-C_{12} alkylthio, halo, or -O-$(CH_2)_m$-[O-$(CH_2)_n$]$_p$-O-(C_1-C_{12} alkyl) or -O-$(CH_2)_q$-X-E; m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4; X is pyrrolidino, piperidino or piperazino; and E is hydrogen, C_1-C_{12} alkyl, C_3-C_{12} cycloalkyl, benzyl or C_3-C_{12} cycloalkylmethyl.

Claim 10 (original): The method of claim 8 wherein the recipient is a human.

Claim 11 (original): The method of claim 9 wherein R' is hydroxy at each occurrence; R^2, R^3, and R^7 are each methyl; R is a moiety of the formula



;

R^4 is hydroxy; R^5 is $-OPO_2HR^a$, where R^a is C_1-C_4 alkyl or C_1-C_4 alkoxy; R^8 is a sugar moiety of the formula



or a pharmaceutically acceptable salt or solvate thereof.

Claim 12 (original): The method of claim 10 wherein R^5 is hydroxy; R is a moiety of the formula



where D is hydrogen or C_3-C_7 alkoxy; R^8 is a moiety of the formula



where R^9 is independently hydrogen, hydroxy, amino, or a moiety of the formula



where R^{9b} is $-OPO_2R^a$, $-OSO_3H$, -H, $-NH_2$, -OH, -0-Pg, or -NH-Pg and n is l, 2, or 3; or a pharmaceutically acceptable salt or solvate thereof.

Claim 13 (currently amended): The method of claim 12 wherein D is n-phenoxy~~;~~ and R^9 is ~~and R^{9a} are~~ independently hydroxy or amino; and R^{9b} is -OH or $-OPO_2R^a$; or a pharmaceutical salt or solvate thereof.

Claim 14 (currently amended): The method of claim 13 wherein R^9 is hydroxy at each occurrence; ~~and R^{9b} is OPO_2R^a, where R^a is methyl or methoxy;~~ or a pharmaceutical salt or solvate thereof.

Claim 15 (original): The method according to Claim 8 wherein the fungal activity arises from one or more fungi selected from the group consisting of *Candida albicans, Aspergillus fumigatis*, and *Candida parapsilosis*.

Claim 16 (previously presented): A method of inhibiting parasitic activity comprising administering to a recipient in need of such inhibition an effective amount of a compound represented by structure I:



wherein R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group; R^1 is independently -H, -OH or –O-Pg; R^2 is -H, $-CH_3$, $-NH_2$, or -NH-Pg; R^3 is -H, $-CH_3$ – CH_2CONH_2, $-CH_2CONH$-Pg, $-CH_2CH_2NH_2$, or-CH_2CH_2NH-Pg; R^5 is -OH, $-OSO_3H$, or – OPO_2HR^a, where R^a is hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, phenyl, phenoxy, *p*-halophenyl, *p*-halophenoxy, *p*-nitrophenyl, *p*-nitrophenoxy, benzyl, benzyloxy, *p*-halobenzyl, *p*-halobenzyloxy, *p*-nitrobenzyl, or *p*-nitrobenzyloxy; R^6 is -H, -OH, or $–OSO_3H$; R^7 is -H or $–CH_3$; R^4 and R^8 are independently, hydrogen, or hydroxy and at least one of R^4 and R^8 is a sugar moiety of the formula



where R^9 is independently -H, -OH, $-N_3$, -O-Pg, $-NH_2$, -NH-Pg, $-OPO_2R^a$, or a second sugar moiety consisting of one to three sugar units selected from the group consisting of



and mixtures thereof, wherein R^{9a} is -H, -OH, $-N_3$, $-NH_2$, -O-Pg, or -NH-Pg, R^{9b} is $-OPO_2R^a$, $-OSO_3H$, -H, $-NH_2$, -OH, -O-Pg, or -NH-Pg, R^{9c} is $-CH_3$, $-CH_2OH$, $-CH_2N_3$, $-CH_2OSO_3H$, $-CH_2NH$-Pg, $-CH_2O$-Pg, $-CO_2H$, or $-CO_2$-Pg, where R^a is as defined above, and no more than one R^9 is represented by said second sugar moiety; and each Pg is independently a protecting group; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

Claim 17 (original): The method of Claim 16 wherein R is



, or

where A, B, C and D arc independently hydrogen, C_1-C_{12} alkyl, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, C_1-C_{12} alkylthio, halo, or -O-$(CH_2)_m$-[O-$(CH_2)_n$]$_p$-O-(C_1-C_{12} alkyl) or -O-$(CH_2)_q$-X-E, m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4; X is pyrrolidino, piperidino or piperazino: and E is hydrogen, C_1-C_{12} alkyl, C_3-C_{12} cycloalkyl, benzyl or C_3-C_{12} cycloalkylmethyl.

Claim 18 (original): The method of claim 16 wherein the recipient is a human.

Claim 19 (original): The method of claim 17 wherein R^1 is hydroxy at each occurrence; R^2, R^3, and R^7 are each methyl; R is a moiety of the formula



;

R^4 is hydroxy; R^5 is -OPO_2HR^a, where R^a is C_1-C_4 alkyl or C_1-C_4 alkoxy; R^8 is a sugar moiety of the formula



;

or a pharmaceutically acceptable salt or solvate thereof.

Claim 20 (original): The method of claim 19 wherein R^5 is hydroxy; R is a moiety of the formula



where D is hydrogen or C_3-C_7 alkoxy; R^8 is a moiety of the formula



where R^9 is independently hydrogen, hydroxy, amino, or a moiety of the formula



where R^{9b} is $-OPO_2R^a$, $-OSO_3H$, -H, $-NH_2$, -OH, -O-Pg, or -NH-Pg and n is 1, 2, or 3; or a pharmaceutically acceptable salt or solvate thereof.

Claim 21 (currently amended): The method of claim 20 wherein D is n-pentoxy~~;~~ and R^9 is ~~and R^{9a} are~~ independently hydroxy or amino; or a pharmaceutical salt or solvate thereof.

Claim 22 (currently amended) The method of claim 21 wherein R^9 is hydroxy at each occurrence; ~~and R^{9b} is OPO_2R^a, where R^a is methyl or methoxy;~~ or a pharmaceutical salt or solvate thereof.

Claim 23 (original): The method according to Claim 16 wherein the parasitic activity arises from *Pneumocystis carinii*.

Claim 24 (previously presented): The compound of claim 1, wherein the Pg of -O-Pg is a hydroxy protecting group, the Pg of -NH-Pg is an amino protecting group, the Pg of -CH_2CONH-Pg is an amino protecting group and the Pg of –CO_2-Pg is a carboxy protecting group.

Claim 25 (previously presented): The method of claim 8 or 16, wherein the Pg of -O-Pg is a hydroxy protecting group, the Pg of -NH-Pg is an amino protecting group, the Pg of -CH_2CONH-Pg is an amino protecting group and the Pg of –CO_2-Pg is a carboxy protecting group.

Claim 26 (new): The compound of claim 1, wherein R^4 and R^8 are each independently a sugar moiety of the formula



where R^9 is independently -H, -OH, -N_3, -O-Pg, -NH_2, -NH-Pg, –OPO_2R^a, or a second sugar moiety consisting of one to three sugar units selected from the group consisting of



and mixtures thereof, wherein R^{9a} is -H, -OH, $-N_3$, $-NH_2$, -O-Pg, or -NH-Pg, R^{9b} is $-OPO_2R^a$, $-OSO_3H$, -H, $-NH_2$, -OH, -O-Pg, or -NH-Pg, R^{9c} is $-CH_3$, $-CH_2OH$, $-CH_2N_3$, $-CH_2OSO_3H$, $-CH_2NH$-Pg, $-CH_2O$-Pg, $-CO_2H$, or $-CO_2$-Pg, where R^a is as defined above, and no more than one R^9 is represented by said second sugar moiety; and each Pg is independently a protecting group; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

Clam 27 (new): The compound of Claim 26 wherein R is



where A, B, C and D are independently hydrogen, C_1-C_{12} alkyl, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, C_1-C_{12} alkylthio, halo, or-O-$(CH_2)_m$-$[O-(CH_2)_n]_p$-O-(C_1-C_{12} alkyl) or -O-$(CH_2)_q$-X-E; m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4; X is pyrrolidino, piperidino or piperazino; and E is

hydrogen, C_1-C_{12} alkyl, C_3-C_{12} cycloalkyl, benzyl or C_3-C_{12} cycloalkylmethyl; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

28 (new): The compound of claim 27, wherein R^1 is hydroxy at each occurrence; R^2, R^3, and R^7 are each methyl; R is a moiety of the formula



R^3 is $-OPO_2HR^a$, and where R^a is C_1-C_4 alkyl or C_1-C_4 alkoxy; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

Claim 29 (new): The compound of claim 28 wherein R^5 is hydroxy; R is a moiety of the formula



where D is hydrogen or C_3-C_7 alkoxy; or a pharmaceutically acceptable salt or solvate thereof.

Claim 30 (new): The method of claim 8, wherein R^4 and R^8 are each independently a sugar moiety of the formula



where R^9 is independently -H, -OH, $-N_3$, -O-Pg, $-NH_2$, -NH-Pg, $-OPO_2R^a$, or a second sugar moiety consisting of one to three sugar units selected from the group consisting of



and mixtures thereof, wherein R^{9a} is -H, -OH, $-N_3$, $-NH_2$, -O-Pg, or -NH-Pg, R^{9b} is $-OPO_2R^a$, $-OSO_3H$, -H, $-NH_2$, -OH, -O-Pg, or -NH-Pg, R^{9c} is $-CH_3$, $-CH_2OH$, $-CH_2N_3$, $-CH_2OSO_3H$, $-CH_2NH$-Pg, $-CH_2O$-Pg, $-CO_2H$, or $-CO_2$-Pg, where R^a is as defined above, and no more than one R^9 is represented by said second sugar moiety; and each Pg is independently a protecting group; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

Clam 31 (new): The method of claim 30, wherein R is



where A, B, C and D are independently hydrogen, C_1-C_{12} alkyl, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, C_1-C_{12} alkylthio, halo, or-O-$(CH_2)_m$-$[O-(CH_2)_n]_p$-O-(C_1-C_{12} alkyl) or -O-$(CH_2)_q$-X-E; m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4; X is pyrrolidino, piperidino or piperazino; and E is

hydrogen, C_1-C_{12} alkyl, C_3-C_{12} cycloalkyl, benzyl or C_3-C_{12} cycloalkylmethyl; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

32 (new): The method of claim 31, wherein R^1 is hydroxy at each occurrence; R^2, R^3, and R^7 are each methyl; R is a moiety of the formula



;

R^3 is $-OPO_2HR^a$, and where R^a is C_1-C_4 alkyl or C_1-C_4 alkoxy; or a pharmaceutically acceptable salt, ester, hydrate, or solvate thereof.

Claim 33 (new): The method of claim 32, wherein R^5 is hydroxy; R is a moiety of the formula



where D is hydrogen or C_3-C_7 alkoxy; or a pharmaceutically acceptable salt or solvate thereof.